Neuropeptide receptors: Novel targets for HIV/AIDS therapeutics

3Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

The vasoactive intestinal peptide/pituitary adenylyl cyclase-activating polypepetide (VPAC) receptors are important for many physiologic functions, including glucose homeostasis, neuroprotection, memory, gut function, modulation of the immune system and circadian function. In addition, VPAC receptors have been shown to function in vitro to modulate the infection of HIV by a signal transduction pathway that appears to regulate viral integration. In this article, the affects of VPAC stimulation on HIV infection will be reviewed and approaches for the development of HIV/AIDS therapeutics that target these receptors will be described. Novel HIV/AIDS therapeutics are urgently required to stem the continued spread of this disease, particularly in underdeveloped countries. Drug design to inhibit signaling through VPAC1 and stimulate signaling through VPAC2 could lead to alternative therapies for the treatment and/or prevention of HIV/AIDS. © 2011 by the authors; licensee MDPI, Basel, Switzerland.

Cite

CITATION STYLE

APA

Branch, D. R. (2011). Neuropeptide receptors: Novel targets for HIV/AIDS therapeutics. Pharmaceuticals, 4(3), 485–493. https://doi.org/10.3390/ph4030485

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free